^
Association details:
| Biomarker: | EGFR mutation + ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + gedatolisib (PF-05212384) (mTOR inhibitor, PI3K inhibitor, mTORC1 inhibitor, mTORC2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC).
Published date:
05/13/2020
Excerpt:
Plasma sample analysis (n = 21) showed that pts with somatic alterations in EGFR (n = 4) had a greater response to therapy (p = 0.066), compared with pts without somatic EGFR alterations.
Secondary therapy:
fulvestrant
DOI:
10.1200/JCO.2020.38.15_suppl.1052
Trial ID:
